Format

Send to

Choose Destination
See comment in PubMed Commons below
Annu Rev Med. 2015;66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Author information

1
The Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, United Kingdom and.

Abstract

The genetic concept of synthetic lethality, in which the combination or synthesis of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to cancer. Already there are promising indications, from clinical trials exploiting this concept by using poly(ADP-ribose) polymerase (PARP) inhibitors in patients with germline BRCA1 or BRCA2 gene mutations, that this approach could be beneficial. We discuss the biological rationale for BRCA-PARP synthetic lethality, how the synthetic lethal approach is being assessed in the clinic, and how mechanisms of resistance are starting to be dissected. Applying the synthetic lethal concept to target non-BRCA-mutant cancers also has clear potential, and we discuss how some of the principles learned in developing PARP inhibitors might also drive the development of additional genetic approaches.

KEYWORDS:

BRCA1; BRCA2; breast cancer; drug resistance; ovarian cancer

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center